Skip to main content

Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

CARLSBAD, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 13-14, 2024 in Snowbird, Utah. John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Exagen’s Chief Financial Officer, will be participating in one-on-one meetings with investors during the event; meetings can be requested through BTIG.

About Exagen Inc.

Exagen is a leading provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision making with the goal of improving patients’ clinical outcomes. Exagen is located in San Diego County, California.

For more information, please visit Exagen.com or follow @ExagenInc on X (formerly known as Twitter).

Contact:
Ryan Douglas
Exagen Inc.
ir@exagen.com
760.560.1525


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.34
+3.19 (1.58%)
AAPL  263.71
-0.17 (-0.06%)
AMD  197.77
-5.31 (-2.61%)
BAC  53.32
+0.58 (1.10%)
GOOG  302.15
-0.67 (-0.22%)
META  639.31
+0.02 (0.00%)
MSFT  399.36
+2.50 (0.63%)
NVDA  186.96
+1.99 (1.08%)
ORCL  155.25
+1.28 (0.83%)
TSLA  410.50
-0.13 (-0.03%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.